<DOC>
	<DOCNO>NCT00003321</DOCNO>
	<brief_summary>RATIONALE : Questionnaires measure quality life may improve ability plan treatment patient cancer esophagus . PURPOSE : This clinical trial study quality-of-life assessment patient cancer esophagus receive treatment .</brief_summary>
	<brief_title>Quality-of-Life Assessment Patients Who Have Cancer Esophagus</brief_title>
	<detailed_description>OBJECTIVES : I . Test psychometric , clinical , cross cultural validity reliability quality-of-life questionnaire EORTC-QLQ-C30 ( version 3.0 ) conjunction esophageal cancer-specific module EORTC QLQ-OES-24 patient esophageal cancer . OUTLINE : This multicenter study . Patients stratify treatment ( potentially curative v purely palliative ) . Patients receive potentially curative treatment stratify accord study treatment ( esophagectomy alone vs esophagectomy plus adjuvant neoadjuvant chemo/radiotherapy v radical radiotherapy without chemotherapy ) . Patients receive purely palliative treatment stratify accord study treatment ( intubation/laser/ethanol injection v palliative chemo/radiotherapy without endoscopic relief dysphagia ) . Patients administer two questionnaire : ( 1 ) The EORTC QLQ-C30 ( version 3.0 ) 30-item questionnaire patient ability function , symptom related cancer treatment , overall health quality life , perceive financial impact cancer treatment . ( 2 ) The EORTC QLQ-OES-24 24-item esophageal cancer-specific questionnaire supplement EORTC QLQ-C30 information disease treatment-related symptom side effect , dysphagia , nutrition , social emotional effect esophageal cancer . Both questionnaire administer treatment . PROJECTED ACCRUAL : 370 patient ( 170 locoregional disease , 200 metastatic disease ) accrue study .</detailed_description>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Group I : Local locoregional primary esophageal esophagogastric cancer Planned esophagectomy without adjuvant neoadjuvant chemotherapy and/or radiotherapy OR Planned radical radiotherapy without chemotherapy Prior endoscopic procedure relieve dysphagia allow No distant liver bone metastasis undergo esophagectomy Group II : Metastatic esophageal cancer local anastomotic recurrence esophageal cancer deem unsuitable esophagectomy Prior palliation endoscopic open intubation , laser treatment , tumor necrosis alcohol injection diathermy , intraluminal radiotherapy allow Prior palliative radiotherapy chemotherapy allow No cerebral metastasis PATIENT CHARACTERISTICS : Age : Any age Performance status : Not specify Life expectancy : Group I : At least 3 month Group II : At least 4 week Hematopoietic : Not specify Hepatic : Not specify Renal : Not specify Other : Mentally fit complete questionnaire undergo interview Aware diagnosis No concurrent second malignancy except basal cell skin cancer No concurrent participation qualityoflife study PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : See Disease Characteristics Endocrine therapy : Not specify Radiotherapy : See Disease Characteristics Surgery : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>stage I esophageal cancer</keyword>
	<keyword>stage II esophageal cancer</keyword>
	<keyword>stage III esophageal cancer</keyword>
	<keyword>stage IV esophageal cancer</keyword>
	<keyword>recurrent esophageal cancer</keyword>
</DOC>